XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.4
Consolidated Investment Products (Tables)
3 Months Ended
Dec. 31, 2024
Consolidated Investment Products [Abstract]  
Schedule of balances of CIPs
The balances related to CIPs included in the Company’s consolidated balance sheets were as follows:
(in millions)December 31,
2024
September 30,
2024
Assets
Cash and cash equivalents$837.1 $1,099.4 
Receivables141.5 217.5 
Investments, at fair value11,897.4 11,034.9 
Total Assets$12,876.0 $12,351.8 
Liabilities
Accounts payable and accrued expenses$861.2 $861.3 
Debt9,055.3 9,341.5 
Other liabilities11.2 39.9 
Total liabilities9,927.7 10,242.7 
Redeemable Noncontrolling Interests1,466.5 687.8 
Stockholders Equity
Franklin Resources, Inc.’s interests1,098.0 1,080.9 
Nonredeemable noncontrolling interests383.8 340.4 
Total stockholders’ equity1,481.8 1,421.3 
Total Liabilities, Redeemable Noncontrolling Interests and Stockholders Equity
$12,876.0 $12,351.8 
Schedule of assets measured at fair value on a recurring basis
Assets of CIPs measured at fair value on a recurring basis were as follows: 
(in millions)Level 1Level 2Level 3NAV as a
Practical
Expedient
Total
as of December 31, 2024
Assets
Cash and cash equivalents of CLOs$519.3 $— $— $— $519.3 
Receivables of CLOs— 80.8 — — 80.8 
Investments
Equity and debt securities485.5 1,501.9 573.5 124.0 2,684.9 
Loans— 9,212.3 0.2 — 9,212.5 
Total Assets Measured at Fair Value$1,004.8 $10,795.0 $573.7 $124.0 $12,497.5 
(in millions)Level 1Level 2Level 3NAV as a
Practical
Expedient
Total
as of September 30, 2024
Assets
Cash and cash equivalents of CLOs$764.3 $— $— $— $764.3 
Receivables of CLOs— 149.6 — — 149.6 
Investments
Equity and debt securities229.7 889.4 550.1 187.1 1,856.3 
Loans— 9,178.1 0.5 — 9,178.6 
Total Assets Measured at Fair Value$994.0 $10,217.1 $550.6 $187.1 $11,948.8 
Schedule of CIPs investments measured at NAV
Investments for which fair value was estimated using reported NAV as a practical expedient consist of a redeemable U.S. equity fund, a redeemable global hedge fund and nonredeemable private debt funds. These investments were as follows:
(in millions)December 31,
2024
September 30,
2024
Nonredeemable investments1
Investments with unknown liquidation periods$53.8 $49.0 
Redeemable investments2
70.2 138.1 
Unfunded commitments3
42.8 42.8 
Schedule of changes in Level 3 assets of CIPs
Changes in Level 3 assets were as follows: 
(in millions)Equity and Debt
Securities
for the three months ended December 31, 2024
Balance at October 1, 2024$550.1 
Gains included in investment and other income (losses) of consolidated investment products, net22.0 
Purchases9.2 
Sales
(11.6)
Net consolidations3.8 
Balance at December 31, 2024$573.5 
Change in unrealized gains included in net income relating to assets held at December 31, 2024$22.3 
(in millions)Equity and Debt
Securities
LoansTotal 
Level 3
Assets
for the three months ended December 31, 2023
Balance at October 1, 2023$584.9 $— $584.9 
Losses included in investment and other income (losses) of consolidated investment products, net(38.1)— (38.1)
Purchases3.8 — 3.8 
Sales
(0.2)— (0.2)
Transfers into Level 31.1 0.6 1.7 
Balance at December 31, 2023$551.5 $0.6 $552.1 
Change in unrealized losses included in net income relating to assets held at December 31, 2023$(37.8)$— $(37.8)
Schedule of valuation techniques and significant unobservable inputs used in Level 3 fair value measurements
Valuation techniques and significant unobservable inputs used in Level 3 fair value measurements were as follows:
(in millions)
as of December 31, 2024Fair ValueValuation TechniqueSignificant Unobservable Inputs
Range (Weighted Average1)
Equity and debt securities$302.2 Market comparable companiesEnterprise value/ Revenue multiple
1.4–28.7 (11.0)
Discount for lack of marketability
5.8%–11.8% (8.0%)
219.1 Market pricingPrivate sale pricing
$0.01–$1,120.00 ($82.93) per share
Discount for lack of marketability
9.7%–13.3% (10.4%)
52.2 Discounted cash flowDiscount rate
6.3%–6.4% (6.3%)
(in millions)
as of September 30, 2024Fair ValueValuation TechniqueSignificant Unobservable Inputs
Range (Weighted Average1)
Equity and debt securities$291.6 Market comparable companiesEnterprise value/ Revenue multiple
1.2–22.8 (10.9)
Discount for lack of marketability
0.1%–10.4% (8.1%)
214.5 Market pricingPrivate sale pricing
$0.01–$1,000.00 ($73.04) per share
Discount for lack of marketability
9.8%–17.5% (11.5%)
44.0 Discounted cash flowDiscount rate6.8%
Schedule of financial instruments of CIPs not measured at fair value
Financial instruments of CIPs that were not measured at fair value were as follows:
(in millions)Fair Value
Level
December 31, 2024September 30, 2024
Carrying
Value
Estimated
Fair Value
Carrying
Value
Estimated
Fair Value
Financial Asset
Cash and cash equivalents1$317.8 $317.8 $335.1 $335.1 
Financial Liabilities
Debt of CLOs1
2 or 3$9,055.3 $8,858.1 $9,341.5 $9,167.3 
Schedule of contractual maturities for debt of CIPs
The contractual maturities for the debt of CLOs at December 31, 2024 were as follows:
(in millions)
for the fiscal years ending September 30,Amount
2025 (remainder of year)$120.1 
2026— 
2027— 
2028— 
2029— 
Thereafter8,935.2 
Total$9,055.3 
Schedule of unpaid principal balance and fair value of investments of CLOs
The unpaid principal balance and fair value of the investments of CLOs were as follows:
(in millions)December 31,
2024
September 30,
2024
Unpaid principal balance$9,420.8 $9,371.9 
Difference between unpaid principal balance and fair value(24.1)(19.8)
Fair Value$9,396.7 $9,352.1